01417nam a2200277   4500001000800000005001700008007000300025008004100028040000800069041000800077100003900085245006000124300002300184520053700207650004800744650002400792650003100816650001000847650003900857650002900896700002900925700002800954773010900982942003101091999001701122ESSALUD20260821102447.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aHaffajee, Rebecca L.eAutor954222  aMarijuana Rescheduling — A Game Changer for Research?  apáginas: 729-731  aOn April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled.  a MEDICAMENTOS, DISPOSITIVOS Y LA FDA954223  aHEMATOLOGÍA97422  aONCOLOGÍA GENERAL954224  aDOLOR  aTRATAMIENTOS EN ONCOLOGÍA953734  aDERECHO SANITARIO948689  aMikos, Robert A. 954225  aCooper, Ziva D. 9542260 022717922650dMassachusetts NEJM GroupoNEJM12tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-21zsqb  c22848d22848